menu
    • menu
    [{"orgOrder":0,"company":"Virogin Biotech","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"VG201","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Virogin Biotech \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VG161","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Shulan (Hangzhou) Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virogin Biotech \/ Shulan (Hangzhou) Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Virogin Biotech \/ Shulan (Hangzhou) Hospital"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15 Dual-Regulated Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VG2025","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Virogin Biotech \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Virogin Biotech

    Menu

    Virogin Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma

                            Details : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cholangiocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 24, 2024

                            Lead Product(s) : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

                            Details : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 13, 2023

                            Lead Product(s) : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

                            Details : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 09, 2023

                            Lead Product(s) : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phaseâ…¡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

                            Details : COVID-19 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 02, 2023

                            Lead Product(s) : COVID-19 mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Shulan (Hangzhou) Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

                            Details : COVID-19 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 02, 2023

                            Lead Product(s) : COVID-19 mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Shulan (Hangzhou) Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

                            Details : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 24, 2023

                            Lead Product(s) : Recombinant Human IL12/15-PDL1B Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VG201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and De...

                            Details : VG201 is a first-in-class oncolytic HSV-1 virus that has enhanced oncolytic activity specifically for tumors expressing carcinoembryonic antigen (CEA) and is designed to produce immune-stimulating cytokines IL-12 and IL-15/IL15Rα.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            September 08, 2022

                            Lead Product(s) : VG201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patie...

                            Details : Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 28, 2022

                            Lead Product(s) : Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VG2025

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Mal...

                            Details : VG2025 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 04, 2022

                            Lead Product(s) : VG2025

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            Virogin Biotech

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VG161

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability...

                            Details : VG161 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 04, 2022

                            Lead Product(s) : VG161

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth